The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (Q50893694)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 June 2013

Language	Label	Description	Also known as
English	The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.	scientific article published on 20 June 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

10

object named as

D C Linch

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

11

object named as

R E Gale

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

author name string

C Allen

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

K Lamb

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

C Evans

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

S Tinsley

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

R Sellar

6

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

M O'Brien

7

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

J L Yin

8

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

A K Burnett

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

publication date

20 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

27

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

1891-1901

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Clinical implications of FLT3 mutations in pediatric AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Implications of NRAS mutations in AML: a study of 2502 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

NCCN Clinical Practice Guidelines Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.186

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50893694&oldid=2210558108"